Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XG004 is an investigational **topical gel** containing a single small-molecule naproxen-pregabalin prodrug conjugate developed by Xgene Pharmaceutical Group for painful osteoarthritis of the knee. Following dermal absorption and enzymatic cleavage, it is designed to deliver naproxen-mediated cyclooxygenase inhibition and pregabalin-mediated modulation of voltage-dependent calcium-channel alpha-2/delta subunits, addressing inflammatory nociceptive pain and neuropathic pain components. In a completed randomized placebo-controlled Phase 1b/2a knee-osteoarthritis study, XG004 topical gel showed acceptable tolerability and exploratory improvements in pain, physical function, and sleep-related outcomes. ([xgenepharm.com](https://www.xgenepharm.com/wp-content/uploads/2023/05/PDF.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on XG004.